Kanker Ovarium : “The Silent Killer”
Abstract
Full Text:
PDFReferences
Jasen P. From the “Silent Killer” to the “Whispering Disease”:Ovarian Cancer and the Uses of Metaphor. Medical History. 2009;53:489-512.
Gajjar K, Ogden G, Mujahid MI, Razvi K. Symptoms and Risk Factors of Ovarian Cancer: A Survey in Primary Care. ISRN Obstet and Gynecol. 2012:1-6.
Nersesian S, Glazebrook H, Toulany J, Grantham S, Boudreau J. Naturally Killing the Silent Killer: NK Cell-Based Immunotherapy for Ovarian Cancer. Front Immunol. 2019;10:1-16.
FIGO. Global ovarian cancer rate rising.2019.
Berek JS, English DP, Longacre TA, Friedlander M. Ovarian, Fallopian Tube, and Peritoneal Cancer. In: Berek JS, editor. Berek and Novak’s Gynecology. 16 ed. Philadelphia: Lippincott Williams & Wilkins; 2020. p. 2541-693.
Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors. International Journal of Women's Health. 2019;11:287-99.
Debashis D, Nath L. Ovarian Cancer - The Silent Killer. J Tumor Res. 2018;3(3):1-6.
Dochez V, Caillon Hln, Vaucel E, Dimet Jrm, Winer N, Ducarme G. Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review. Journal of Ovarian Research. 2019;12(28):1-9.
Maharaj AG, Jacobs I, Menon U. Ovarian cancer-tumor marker and screening. In: Bereck JS, Hacker NF, editors. Gynecology Oncology. 6 ed. Philadeplhia: Wolters Kluwer Health; 2015. p. 443-663.
Timmerman D, Valentin L, Bourne TH, Collins WP, Verrelst H, Vergote I. Terms, definitions and measurements to describe the sonographic features of adnexal tumors: a consensus opinion from the International Ovarian Tumor Analysis (IOTA) group. Ultrasound Obstet Gynecol. 2000;16:500-5.
Alcazar JL. Ultrasound for differential diagnosis of adnexal masses. Boca Raton: Taylor and Francis Group; 2018.
DOI: http://dx.doi.org/10.24198/obgynia.v3i1.192
Refbacks
- There are currently no refbacks.